BR112022024296A2 - Formulações de anticorpos e seus usos - Google Patents

Formulações de anticorpos e seus usos

Info

Publication number
BR112022024296A2
BR112022024296A2 BR112022024296A BR112022024296A BR112022024296A2 BR 112022024296 A2 BR112022024296 A2 BR 112022024296A2 BR 112022024296 A BR112022024296 A BR 112022024296A BR 112022024296 A BR112022024296 A BR 112022024296A BR 112022024296 A2 BR112022024296 A2 BR 112022024296A2
Authority
BR
Brazil
Prior art keywords
antibody formulations
antibody
formulations
formulation
eculizumab
Prior art date
Application number
BR112022024296A
Other languages
English (en)
Inventor
Ip Anna
Patel Ketaki
Talley Clea
J Treuheit Michael
Zhang Jun
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of BR112022024296A2 publication Critical patent/BR112022024296A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

FORMULAÇÕES DE ANTICORPOS E SEUS USOS. São proporcionadas aqui formulações de anticorpos e métodos de preparação e uso de tais formulações. A formulação pode ser para administração intravenosa. Em algumas modalidades, a formulação é para administração subcutânea. Em algumas modalidades, a formulação compreende um anticorpo anti-C5, tal como eculizumab.
BR112022024296A 2020-05-29 2021-05-28 Formulações de anticorpos e seus usos BR112022024296A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063031634P 2020-05-29 2020-05-29
PCT/US2021/034987 WO2021243284A1 (en) 2020-05-29 2021-05-28 Antibody formulations and uses thereof

Publications (1)

Publication Number Publication Date
BR112022024296A2 true BR112022024296A2 (pt) 2023-04-25

Family

ID=76859714

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022024296A BR112022024296A2 (pt) 2020-05-29 2021-05-28 Formulações de anticorpos e seus usos

Country Status (8)

Country Link
EP (1) EP4157353A1 (pt)
JP (1) JP2023528305A (pt)
KR (1) KR20230019145A (pt)
CN (1) CN115697406A (pt)
AU (1) AU2021281445A1 (pt)
BR (1) BR112022024296A2 (pt)
CA (1) CA3183934A1 (pt)
WO (1) WO2021243284A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023168255A1 (en) * 2022-03-02 2023-09-07 Amgen Inc. Compositions of anti-c5 monoclonal antibody

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5853975A (en) * 1994-08-23 1998-12-29 Millennium Pharmaceuticals, Inc. Methods for identifying compositions for the treatment of body weight disorders, including obesity
EA201791366A1 (ru) * 2014-12-19 2018-02-28 Чугаи Сейяку Кабусики Кайся Антитела к c5 и способы их применения
AU2018261951A1 (en) * 2017-05-05 2019-10-31 Amgen Inc. Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration

Also Published As

Publication number Publication date
KR20230019145A (ko) 2023-02-07
CA3183934A1 (en) 2021-12-02
AU2021281445A1 (en) 2022-12-22
WO2021243284A1 (en) 2021-12-02
CN115697406A (zh) 2023-02-03
JP2023528305A (ja) 2023-07-04
EP4157353A1 (en) 2023-04-05

Similar Documents

Publication Publication Date Title
Jansen of Lorkeers et al. Similar effect of autologous and allogeneic cell therapy for ischemic heart disease: systematic review and meta-analysis of large animal studies
CO2021005774A2 (es) Lípidos con amina ionizables
MX2022013320A (es) Portadores lipidos nanoestructurados y emulsiones estables y usos de los mismos.
CL2019000245A1 (es) Moduladores nmda espiro-lactam y métodos de uso de los mismos.
EA202191559A1 (ru) Модифицированные аминовые липиды
BR112022024296A2 (pt) Formulações de anticorpos e seus usos
UY37952A (es) Formulaciones de un inhibidor de la quinasa trk macrocíclica
CL2019000248A1 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
CL2019000247A1 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos.
CL2019000249A1 (es) Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos.
CL2019000246A1 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos.
BR112014006608A2 (pt) formulações com base em dispersões sólidas
PE20150226A1 (es) Agentes terapeuticos para administracion subcutanea optimizados
BR112022011321A2 (pt) Compostos, polímeros, dispositivos e seus usos
BR112018072113A2 (pt) excipiente à base de proteínas para ingredientes farmacêuticos ativos
CO2020004407A2 (es) Formulaciones de espora de nutriente y usos de las mismas
CO2022017622A2 (es) Inhibidores de quinasa nek7
AR121895A1 (es) Formulación estable
CO2023008271A2 (es) Compuesto de heteroarilcarboxamida
AR108562A1 (es) Método para la preparación del conjugado hialuronidasa con derivados de piperazina de polietileno y la aplicación del conjugado obtenido
ES2058228T3 (es) Compuestos activos sobre el sistema cardiovascular.
BR112023021812A2 (pt) Composição vacinal adjuvantada e métodos
BR112022000364A2 (pt) Sistemas fluorescentes para imagiologia biológica e seus usos
EA202092077A1 (ru) Местные составы, содержащие стронций и метилсульфонилметан (мсм), и способы лечения
MX2021000037A (es) Nueva formulacion estable de alta concentracion para anticuerpos anti-fxia.